Airfinity launched ID-Vx and ID-Tx

Posted on Jul 8, 2022

Airfinity has launched two new products, ID-Vx and ID-Tx. These new solutions combine to provide a holistic overview of all vaccine and treatment (including prophylactics) developments within the infectious disease space*. Candidates and changes to the landscape, clinical trials, new approvals, new deals, media and KOL discussions are all covered in a monthly report along with a topical deep dive.

What is ID-Vx?

ID-Vx provides a full, top-line overview of the vaccine development landscape across infectious diseases (excluding COVID-19, RSV and Influenza). We track ~1000 candidates including pre-clinical and clinical candidates, across ~80 infectious diseases.

What is ID-Tx?

ID-Tx provides a full, top-line overview of the prophylactic and therapeutic development landscape across infectious diseases (excluding COVID-19, RSV and Influenza). We track ~850 candidates including pre-clinical and clinical candidates, across ~100 infectious diseases.

Both ID-Vx and ID-Tx provides a monthly report outlining:

→ An overview of candidates in development and changes to the candidate landscape

→ Clinical trial overviews including new locations and announced timelines of completion

→ New approvals

→ New deals (co-development, licensing, partnership, acquisition)

→ Media and Press Release overviews

→ KOL social media discussions

→ A deep dive of interest

What is the difference between ID-Tx and ID-Vx, and Science360?

Unlike ID-Vx and ID-Tx, which provide a high-level overview of the entire infectious disease landscape and developments, Science360 is Airfinity’s premium offering. Providing deeper analytics, tool building and modelling for a specific infectious disease.

Airfinity already provides full Science360 offerings for COVID-19, influenza and RSV but is able to build a Science360 offering for any infectious disease area of interest. A Science360 product covers all data within the ID-Vx and ID-Tx products but also includes conference coverage, publications, efficacy and safety results, epidemiology and other deeper analytics, tools, predictive models and forecasts.

To request a sample report and analysis for Pneumococcal Science360, get in touch here.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022